Drug Profile

Elsunersen - Praxis-Precision-Medicines

Alternative Names: PRAX-222

Latest Information Update: 15 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Praxis Precision Medicines
Class Antiepileptic drugs; Antisense oligonucleotides
Mechanism of Action Gene silencing; SCN2A protein expression inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Epilepsy
New Molecular Entity Yes

Highest Development Phases

Phase III Epilepsy

Most Recent Events

09 Dec 2025 Praxis Precision Medicines completes type C meeting with US FDA
04 Aug 2025 Phase-III clinical trials in Epilepsy (In adolescents, In children, In neonates, In infants) in USA (Intrathecal) (NCT07019922)
28 Feb 2025 Praxis Precision Medicines plans a registrational EMBRAVE3 trial for Epilepsy in the middle of 2025 (NCT07019922)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com